TY  - JOUR
  - Lambe, T,Carey, JB,Li, YY,Spencer, AJ,van Laarhoven, A,Mullarkey, CE,Vrdoljak, A,Moore, AC,Gilbert, SC
  - 2013
  - January
  - Scientific Reports
  - Immunity Against Heterosubtypic Influenza Virus Induced By Adenovirus And MVA Expressing Nucleoprotein And Matrix Protein-1
  - Validated
  - ()
  - T-CELLS VACCINIA VIRUS PROTECTIVE IMMUNITY PANDEMIC INFLUENZA INDUCTION IMMUNOGENICITY VACCINATION INFECTION EFFICACY ANTIGEN
  - 3
  - Alternate prime/boost vaccination regimens employing recombinant replication-deficient adenovirus or MVA, expressing Influenza A virus nucleoprotein and matrix protein 1, induced antigen-specific T cell responses in intradermally (ID) vaccinated mice; with the strongest responses resulting from Ad/MVA immunization. In BALB/C mice the immunodominant response was shifted from the previously identified immunodominant epitope to a novel epitope when the antigen was derived from A/Panama/2007/1999 rather than A/PR/8. Alternate immunization routes did not affect the magnitude of antigen-specific systemic IFN-gamma response, but higher CD8(+) T-cell IFN-gamma immune responses were seen in the bronchoalveolar lavage following intransal (IN) boosting after intramuscular (IM) priming, whilst higher splenic antigen-specific CD8(+) T cell IFN-gamma was seen following IM boosting. Partial protection against heterologous influenza virus challenge was achieved following either IM/IM or IM/IN but not ID/ID immunization. These data may be of relevance for the design of optimal immunization regimens for human influenza vaccines, especially for influenza-naive infants.
  - ARTN 1443
DA  - 2013/01
ER  - 

@article{V206307465,
   = {Lambe,  T and Carey,  JB and Li,  YY and Spencer,  AJ and van Laarhoven,  A and Mullarkey,  CE and Vrdoljak,  A and Moore,  AC and Gilbert,  SC },
   = {2013},
   = {January},
   = {Scientific Reports},
   = {Immunity Against Heterosubtypic Influenza Virus Induced By Adenovirus And MVA Expressing Nucleoprotein And Matrix Protein-1},
   = {Validated},
   = {()},
   = {T-CELLS VACCINIA VIRUS PROTECTIVE IMMUNITY PANDEMIC INFLUENZA INDUCTION IMMUNOGENICITY VACCINATION INFECTION EFFICACY ANTIGEN},
   = {3},
   = {{Alternate prime/boost vaccination regimens employing recombinant replication-deficient adenovirus or MVA, expressing Influenza A virus nucleoprotein and matrix protein 1, induced antigen-specific T cell responses in intradermally (ID) vaccinated mice; with the strongest responses resulting from Ad/MVA immunization. In BALB/C mice the immunodominant response was shifted from the previously identified immunodominant epitope to a novel epitope when the antigen was derived from A/Panama/2007/1999 rather than A/PR/8. Alternate immunization routes did not affect the magnitude of antigen-specific systemic IFN-gamma response, but higher CD8(+) T-cell IFN-gamma immune responses were seen in the bronchoalveolar lavage following intransal (IN) boosting after intramuscular (IM) priming, whilst higher splenic antigen-specific CD8(+) T cell IFN-gamma was seen following IM boosting. Partial protection against heterologous influenza virus challenge was achieved following either IM/IM or IM/IN but not ID/ID immunization. These data may be of relevance for the design of optimal immunization regimens for human influenza vaccines, especially for influenza-naive infants.}},
   = {ARTN 1443},
  source = {IRIS}
}